Nirav K. Mehta

CORONA Remedies reported unaudited Q2FY27 revenue of ₹441.2 crore, up 22.2% YoY, with EBITDA at ₹96 crore. The company achieved its highest ever revenue, outpacing IPM growth by 1.9x and maintaining 2

CORONA Remedies reported Q2 FY27 unaudited standalone revenue of ₹441.17 crore, up 22.2% YoY, with net profit of ₹60.18 crore. The Board approved Q2 and H1 FY27 financial results following Audit Commi